Channel Therapeutics (CHRO) is providing a statement regarding Vertex Pharmaceutical’s (VRTX) recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. Characteristics of Selective NaV1.7 Inhibition: NaV1.7 is a well-studied drug target with strong genetic validation – studies of inheritable pain disorders demonstrate that the spectrum of NaV1.7 activity validates the importance of this target. Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing pain.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRO:
- Channel Therapeutics announces data for formulation of NaV1.7 inhibitor
- Chromocell changes name to Channel Therapeutics, provides program updates
- Chromocell Therapeutics Rebrands to Focus on Pain Treatments
- Chromocell Therapeutics Merges into Channel Therapeutics
- Chromocell unveils injectable depot program for treating surgical pain